Procalcitonin as Biomarker of Infection: Implications for Evaluation and Treatment
Procalcitonin as Biomarker of Infection: Implications for Evaluation and Treatment
复制标题
DOI：
10.1097/mjt.0000000000000210
复制
发表时间：
2017-05-01
影响因子：
4.2
通讯作者：
Pinheiro, Isabel Duque
中科院分区：
文献类型：
--
作者：
Goncalves, Pedro Falcao;Falcao, Luiz Menezes;Pinheiro, Isabel Duque
降钙素原（PCT）是一种快速可测量的标志物，被认为对脓毒症和感染具有高灵敏度和特异性。进行了文献检索，以评价PCT作为感染过程中诊断和预后工具的能力及其监测抗生素治疗的能力。PCT水平在细菌和真菌感染中升高，但在病毒感染中不升高，与未感染患者相比，菌血症患者的PCT水平显著更高（2.5 vs 0.3 ng/mL; P <0.0001）。PCT值为0.1 ng/mL时需要进行微生物检测，> 1.0 ng/mL则表明存在菌血症。PCT指导的抗生素治疗算法使抗生素治疗的需求减少了约50%。PCT在临床实践中是一种很有前途的测试，除了现有的工具外，还可以决定是否引入抗生素治疗，而不会忽视临床评估，并显著降低成本。
Procalcitonin (PCT) is a quickly measurable marker, assumed to have high sensitivity and specificity for sepsis and infection. A literature search was conducted to evaluate PCT ability as a diagnostic and prognostic tool in infectious processes and its ability to monitor the antibiotic therapy. PCT level is increased in bacterial and fungal infections, but not in viral infections, with a significantly higher level in patients with bacteremia compared with uninfected patients (2.5 vs. 0.3 ng/mL; P < 0.0001). A PCT value of 0.1 ng/mL needs microbiological tests, and >1.0 ng/mL is indicative of bacteremia. Antibiotic treatment algorithms guided by PCT decreased the need for antibiotic treatment in approximately 50%. PCT is a promising test in clinical practice to decide the introduction of antibiotic therapy in addition to the existing tools, without neglecting the clinical assessment, with a significant decrease in costs.